Tendon sheath disorder

This study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a…

This phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are…

This study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…

This Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a …

This phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…

This study was designed to compare two standard surgical techniques for bicep tenodesis—using one anchor or two mini anchors—to see which keeps the tendon in place better. It planned to track tendon movement with X-rays right after surgery, at 2 weeks, and at 6 months. However, t…